Abstract
Genetic polymorphisms in drug metabolizing enzymes and drug-drug interactions are major sources of inadequate drug exposure and ensuing adverse effects or insufficient responses. The current challenge in assessing drug-drug gene interactions (DDGI) for the development of precise dose adjustment recommendation systems is to take into account both simultaneously. Here, we analyze the static models of DDGI from in vivo data and focus on the concept of phenoconversion to model inhibition and genetic polymorphisms jointly. These models are applicable to datasets where pharmacokinetic information is missing and are being used in clinical support systems and consensus dose adjustment guidelines. We show that all such models can be handled by the same formal framework, and that models that differ at first sight are all versions of the same linear phenoconversion model. This model includes the linear pharmacogenetic and inhibition models as special cases. We highlight present challenges in this endeavour and the open issues for future research in developing DDGI models for recommendation systems.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by the Austrian Science Fund (FWF) and by the German Federal Ministry of Eduction and Research (BMBF)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Correction of typos
Data Availability
The manuscript contains proofs of relationships between pharmacogenetic models, and the proofs are included in the manuscript
List of abbreviations
- DDGI
- drug-drug-gene interaction
- DME
- drug metabolizing enzyme
- PM, IM, NM, RM, UM
- poor, intermediate, normal, rapid, ultrarapid metabolizer phenotype
- XM
- a metabolizer phenotype variable
- AUCPM, AUCNM, AUCXM, AUC*
- area under curve measured in PMs, NMs, in the phenotype XM, and in the presence of an inhibitor
- CLPM, CLNM, CLXM, CL*
- clearance measured in PMs, NMs, in the phenotype XM, and in the presence of an inhibitor
- AS
- activity score of a genetic polymorphic DME, i.e. one where the value of a PM is zero
- RAS
- relative activity score of a genetic polymorphic DME, i.e. one where the value of a NM is zero
- FD
- a variable estimated in phenotypic models of pharmacogenetic effects, representing the importance of a DME in the metabolism of the drug D
- CR
- a variable in static models of inhibition representing the fraction contributed by a DME in the hepatic metabolism of a drug, being equivalent to FD or to a rescaled version thereof
- IR
- inhibition rate, a variable representing the effect of an inhibitor on the activity of a DME ranging from zero (no inhibition) to unity (full inhibition)
- Iapp
- apparent time-averaged concentration of the inhibitor in the liver
- Ki
- inhibition constant
- IX
- a variable in static models of drug-drug-gene interactions, equivalent to −IR.
- FA
- a variable in static models of drug-drug-gene interactions representing an activity score with value zero in PMs and unity in NMs
